[{"evidenceId":11681,"evidenceType":"GENE_BACKGROUND","shortDesc":null,"desc":"The NRAS gene encodes a membrane-associated GTPase that controls intracellular oncogenic MAPK and PI3K signaling pathways. Activating NRAS mutations lock the enzyme in an active state causing increased cellular proliferation via hyperactivating these downstream pathways (PMID: 20194776, 21993244). NRAS mutations are common in thyroid cancer, ovarian cancers, melanoma and hematological cancers (PMID: 21993244, 22589270, 24651010). NRAS is also important during development with germline mutations enhancing stimulus-dependent MAPK activation and accounting for some cases of Noonan syndrome (PMID: 19966803). NRAS mutations and upregulation can also provide resistance to cancer therapies, including epidermal growth factor receptor (EGFR) and BRAF inhibitors (PMID: 2238947, 20619739, 25110411, 24024839).","id":null,"lastEdit":"2017-04-19","status":null,"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","name":"neuroblastoma RAS viral oncogene homolog","oncogene":true,"curatedIsoform":"ENST00000369535","curatedRefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"tsg":false},"articles":[{"pmid":"20194776","title":"Allosteric modulation of Ras positions Q61 for a direct role in catalysis.","journal":"Proceedings of the National Academy of Sciences of the United States of America","pubDate":"2010 Mar 16","volume":"107","issue":"11","pages":"4931-6","authors":"Buhrman G et al","elocationId":"doi: 10.1073/pnas.0912226107","link":null,"reference":"Buhrman G et al. Proceedings of the National Academy of Sciences of the United States of America. 2010 Mar 16;107(11)4931-6.","abstract":null},{"pmid":"24651010","title":"Dragging ras back in the ring.","journal":"Cancer cell","pubDate":"2014 Mar 17","volume":"25","issue":"3","pages":"272-81","authors":"Stephen AG et al","elocationId":"doi: 10.1016/j.ccr.2014.02.017","link":null,"reference":"Stephen AG et al. Cancer cell. 2014 Mar 17;25(3)272-81.","abstract":null},{"pmid":"24024839","title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","journal":"The New England journal of medicine","pubDate":"2013 Sep 12","volume":"369","issue":"11","pages":"1023-34","authors":"Douillard JY et al","elocationId":"doi: 10.1056/NEJMoa1305275","link":null,"reference":"Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.","abstract":null},{"pmid":"25110411","title":"Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.","journal":"World journal of gastroenterology","pubDate":"2014 Aug 7","volume":"20","issue":"29","pages":"9732-43","authors":"De Stefano A et al","elocationId":"doi: 10.3748/wjg.v20.i29.9732","link":null,"reference":"De Stefano A et al. World journal of gastroenterology. 2014 Aug 7;20(29)9732-43.","abstract":null},{"pmid":"21993244","title":"RAS oncogenes: weaving a tumorigenic web.","journal":"Nature reviews. Cancer","pubDate":"2011 Oct 13","volume":"11","issue":"11","pages":"761-74","authors":"Pylayeva-Gupta Y et al","elocationId":"doi: 10.1038/nrc3106","link":null,"reference":"Pylayeva-Gupta Y et al. Nature reviews. Cancer. 2011 Oct 13;11(11)761-74.","abstract":null},{"pmid":"22589270","title":"A comprehensive survey of Ras mutations in cancer.","journal":"Cancer research","pubDate":"2012 May 15","volume":"72","issue":"10","pages":"2457-67","authors":"Prior IA et al","elocationId":"doi: 10.1158/0008-5472.CAN-11-2612","link":null,"reference":"Prior IA et al. Cancer research. 2012 May 15;72(10)2457-67.","abstract":null},{"pmid":"20619739","title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","journal":"The Lancet. Oncology","pubDate":"2010 Aug","volume":"11","issue":"8","pages":"753-62","authors":"De Roock W et al","elocationId":"doi: 10.1016/S1470-2045(10)70130-3","link":null,"reference":"De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.","abstract":null},{"pmid":"19966803","title":"A restricted spectrum of NRAS mutations causes Noonan syndrome.","journal":"Nature genetics","pubDate":"2010 Jan","volume":"42","issue":"1","pages":"27-9","authors":"Cirstea IC et al","elocationId":"doi: 10.1038/ng.497","link":null,"reference":"Cirstea IC et al. Nature genetics. 2010 Jan;42(1)27-9.","abstract":null},{"pmid":"2238947","title":"[Antimicrobial containing impression and model materials for infection prevention in the laboratory].","journal":"Zahnarztliche Praxis","pubDate":"1990 Aug 10","volume":"41","issue":"8","pages":"290-2, 294-5","authors":"Welker D et al","elocationId":"","link":null,"reference":"Welker D et al. Zahnarztliche Praxis. 1990 Aug 10;41(8)290-2, 294-5.","abstract":null}]},{"evidenceId":11680,"evidenceType":"GENE_SUMMARY","shortDesc":null,"desc":"NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.","id":null,"lastEdit":"2017-04-19","status":null,"gene":{"entrezGeneId":4893,"hugoSymbol":"NRAS","name":"neuroblastoma RAS viral oncogene homolog","oncogene":true,"curatedIsoform":"ENST00000369535","curatedRefSeq":"NM_002524.4","geneAliases":["CMNS","NS6","ALPS4","N-ras","NRAS1","NCMS"],"tsg":false},"articles":[]}]